Chronic Airway Disease and Multimorbidity Cohort
Recruiting · NCT06798077 · Observational (researchers observe without assigning treatment) · Lead sponsor: China-Japan Friendship Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization. Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.
Who can take part
Inclusion criteria
- Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age;
- The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis".
Exclusion criteria
- Patients were unable to undergo spirometry during the stabilization period;
- Expected survival is less than 1 month;
- Refusal to sign an informed consent form;
- Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion;
- Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.
Where it is running
9 locations listed.
- National Center for Respiratory Medicine, China-Japan Friendship Hospital - Beijing, Beijing Municipality, China
- Zhujiang Hospital of Southern Medical University - Guangzhou, Guangdong, China
- Henan Provincial People's Hospital - Zhengzhou, Henan, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan, Hubei, China
- The Second Xiangya Hospital of Central South University - Changsha, Hunan, China
- The First Affiliated Hospital of China Medical University - Shenyang, Liaoning, China
- The Second Affiliated Hospital of Xi'an Jiaotong University - Xi'an, Shaanxi, China
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University - Shanghai, Shanghai Municipality, China
- West China Hospital of Sichuan University - Chengdu, Sichuan, China